

Medicinal Foodstuffs. XXI.¹⁾ Structures of New Cucurbitane-Type Triterpene Glycosides, Goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h, and New Oleanane-Type Triterpene Saponins, Goyasaponins I, II, and III, from the Fresh Fruit of Japanese *Momordica charantia* L.

Toshiyuki MURAKAMI, Akihito EMOTO, Hisashi MATSUDA, and Masayuki YOSHIKAWA*

Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto 607–8414, Japan.

Received July 7, 2000; accepted September 19, 2000

Eight cucurbitane-type triterpene glycosides called goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h and three oleanane-type triterpene saponins termed goyasaponins I, II, and III were isolated from the fresh fruit of Japanese *Momordica charantia* L. (Cucurbitaceae) together with five known cucurbitane-type triterpene glycosides momordicosides A, C, F₁, I, and K. The structures of goyaglycosides and goyasaponins were elucidated on the basis of chemical and physicochemical evidence.

Key words *Momordica charantia*; goyaglycoside; goyasaponin; nigauri; cucurbitane-type triterpene glycoside; oleanane-type triterpene saponin

The Cucurbitaceae plant *Momordica* (*M.*) *charantia* L. (Japanese name “Tsurureishi”) is cultivated as a vegetable in Asian countries. In Chinese, Indian Ayurvedic, and Indonesian Jamu traditional medicines, the fruit of this plant has been used as a bitter stomachic, a laxative, an antidiabetic, and an anthelmintic for children. Recently, the alcoholic extract from the fruit of *M. charantia* originated in Sri Lanka was reported to inhibit the increase of serum glucose in glucose-loaded rats.²⁾ As chemical constituents of the fruit, many cucurbitane-type triterpene glycosides were reported,³⁾ but the constituents responsible for the inhibition of glucose absorption have not been identified. In the course of our studies on the bioactive constituents of medicinal foodstuffs,^{1,4)} we have also characterized many triterpene glycosides from the fruit of *M. charantia* originated in Japan, Thailand, Indonesia, India, and Sri Lanka. In this paper, we present the isolation and structure elucidation of goyaglycosides-a (1), -b (2), -c (3), -d (4), -e (5), -f (6), -g (7), and -h

(8) and goyasaponins I (9), II (10), and III (11) from the fresh fruit of Japanese *M. charantia*, which is commonly called “nigauri” or “goya”.

The cucurbitane- and oleanane-type triterpene glycosides of the fresh fruit of Japanese *M. charantia* were separated by the procedures shown in Chart 1. The methanolic extract obtained from the fresh fruit of *M. charantia* was partitioned into an ethyl acetate and a water mixture to give an ethyl acetate extract and an aqueous phase. The aqueous phase was extracted with 1-butanol to furnish a 1-butanol extract and an aqueous extract. The 1-butanol extract was subjected to normal- and reversed-phase silica gel column chromatography and finally HPLC to give goyaglycosides-a (1), -b (2), -c (3), -d (4), -e (5), -f (6), -g (7), and -h (8), goyasaponins I (9), II (10), and III (11), and momordicosides A^{3a)} (12), C^{3b)} (13), F₁^{3c)} (14), I^{3c)} (15), and K^{3d)} (16).

Structures of Cucurbitane-Type Triterpene Glycosides (1–8) Goyaglycoside-a (1) was obtained as a white pow-




Chart 1

* To whom correspondence should be addressed. e-mail: shoyaku@mb.kyoto-phu.ac.jp




Chart 2

der with negative optical rotation ($[\alpha]_D^{26} -101.4^\circ$). The IR spectrum of **1** showed strong absorption bands at 3423 and 1080 cm^{-1} suggestive of a glycosidic function. In the negative- and positive-ion FAB-MS of **1**, quasimolecular ion peaks were observed at m/z 647 ($M-H$)⁻ and m/z 649 ($M+H$)⁺ and the molecular formula $C_{37}H_{60}O_9$ was determined by high-resolution MS measurement. Furthermore, fragment ion peaks of **1** were observed at m/z 617 ($M-CH_3O$)⁻ and m/z 455 ($M-CH_3O-C_6H_{10}O_5$)⁻. Acid hydrolysis of **1** with 5% aqueous sulfuric acid (H_2SO_4)-1,4-dioxane (1 : 1, v/v) furnished D-glucose, which was identified by GLC analysis of the thiazolidine derivative,⁵ while enzymatic hydrolysis of **1** with naringinase furnished 19(*R*)-methoxy-5 β ,19-epoxycucurbita-6,23-diene-3 β ,25-diol (**17**).⁶ The ¹H-NMR and ¹³C-NMR spectra of **1**, which were assigned by various NMR experiments,⁷ showed signals due to the aglycone moiety [δ 0.86, 0.89, 0.90, 1.47 (all s, 29, 30, 18, 28-

H_3), 0.97 (d, $J=5.3$ Hz, 21- H_3), 1.54 (s, 26, 27- H_3), 3.12 (dd-like, 8-H), 3.44 (s, 19-OMe), 3.73 (br s, 3-H), 4.84 (s, 19-H), 5.62 (dd, $J=3.6, 9.6$ Hz, 7-H), 5.92 (m, 23, 24-H), 6.16 (dd, $J=2.0, 9.6$ Hz, 6-H)] and a β -D-glucopyranosyl moiety [δ 4.95 (d, $J=7.6$ Hz, 1'-H)]. The bonding position of the β -D-glucopyranosyl moiety in **1** was clarified by HMBC experiment, which showed a long-range correlation between the 1'-proton of the glucopyranosyl moiety and the 3-carbon of the aglycone moiety. Consequently, the structure of goyaglycoside-a was determined to be 19(*R*)-methoxy-5 β ,19-epoxycucurbita-6,23-diene-3 β ,25-diol 3-*O*- β -D-glucopyranoside (**1**).⁸

Goyaglycoside-b (**2**), obtained as a white powder with negative optical rotation, liberated D-allose by acid hydrolysis, which was also identified by GLC analysis of the thiazolidine derivative.⁵ The molecular formula $C_{37}H_{60}O_9$ of **2** was determined from quasimolecular ion peaks [m/z 647 ($M-H$)⁻ and 649 ($M+H$)⁺] in the negative- and positive-ion FAB-MS and




Chart 3

by high-resolution MS measurement. The $^1\text{H-NMR}$ (pyridine- d_5) and $^{13}\text{C-NMR}$ (Table 1) spectra⁷⁾ of **2** showed signals due to a 19(*R*)-methoxy-5 β ,19-epoxycucurbita-6,23-diene-3 β ,25-diol moiety [δ 0.83, 0.89, 0.90, 1.44 (all s, 29, 30, 18, 28- H_3), 0.98 (d, $J=5.3$ Hz, 21- H_3), 1.54 (s, 26, 27- H_3), 3.13 (dd-like, 8-H), 3.50 (s, 19-OMe), 3.70 (br s, 3-H), 4.88 (s, 19-H), 5.61 (dd, $J=3.3, 9.6$ Hz, 7-H), 5.92 (m, 23, 24-H), 6.15 (dd, $J=2.0, 9.6$ Hz, 6-H)] together with an β -D-allopyranosyl moiety [δ 5.44 (d, $J=7.6$ Hz, 1'-H)]. In the HMBC experiment of **2**, a long-range correlation was observed between the 1'-proton of the allopyranosyl moiety and the 3-carbon of the aglycone. Finally, comparison of the NMR data for **2** with those for **1** led us to formulate the structure of goyaglycoside-b as 19(*R*)-methoxy-5 β ,19-epoxycucurbita-6,23-diene-3 β ,25-diol 3-*O*- β -D-allopyranoside (**2**).⁸⁾

Goyaglycosides-c (**3**) and -d (**4**), obtained as a white powder with negative optical rotation, were found to have the same molecular formula, $\text{C}_{38}\text{H}_{62}\text{O}_9$, which was determined from the quasimolecular ion peaks [m/z 661 ($\text{M}-\text{H})^-$, m/z 685 ($\text{M}+\text{Na})^+$] in the negative- and positive-ion FAB-MS and by high-resolution MS measurement. Acid hydrolysis of **3** furnished D-glucose, while D-allose was obtained by acid hydrolysis of **4**.⁵⁾ Enzymatic hydrolysis of **3** with naringinase furnished 19(*R*),25-dimethoxy-5 β ,19-epoxycucurbita-6,23-dien-3 β -ol (**18**).⁶⁾

The carbon and proton signals in the $^1\text{H-NMR}$ (pyridine- d_5) and $^{13}\text{C-NMR}$ (Table 1) spectra⁷⁾ of **3** and **4** were superimposable on those of **1** and **2**, except for signals due to the 25-methoxyl group, respectively. The $^1\text{H-NMR}$ spectra of **3** and **4** showed two methoxyl signals to the 19- [**3**: δ 3.44 (s);

4: δ 3.50 (s)] and 25-positions [**3**, **4**: δ 3.22 (s)]. Furthermore, in the HMBC experiments on **3** and **4**, long-range correlations were observed between the 25-methoxyl protons and the 25-carbon and between the 1'-proton [**3**: δ 4.95 (d, $J=7.6$ Hz); **4**: δ 5.43 (d, $J=7.7$ Hz)] and the 3-carbon. Consequently, the structures of goyaglycosides-c and -d were characterized as 19(*R*),25-dimethoxy-5 β ,19-epoxycucurbita-6,23-dien-3 β -ol 3-*O*- β -D-glucopyranoside (**3**)⁸⁾ and 19(*R*),25-dimethoxy-5 β ,19-epoxycucurbita-6,23-dien-3 β -ol 3-*O*- β -D-allopyranoside (**4**).⁸⁾

Goyaglycoside-e (**5**) was obtained as a white powder with negative optical rotation ($[\alpha]_D^{28} -75.6^\circ$). The molecular formula $\text{C}_{42}\text{H}_{68}\text{O}_{13}$ was determined from the negative- [m/z 779 ($\text{M}-\text{H})^-$] and positive- [m/z 781 ($\text{M}+\text{H})^+$] ion FAB-MS and by high-resolution MS measurement. Furthermore, a fragment ion peak was observed at m/z 617 ($\text{M}-\text{C}_6\text{H}_{11}\text{O}_5$)⁻ in the negative-ion FAB-MS of **5**. Acid hydrolysis of **5** with 5% aqueous H_2SO_4 -1,4-dioxane (1:1, v/v) furnished D-allose and D-glucose.⁵⁾ Enzymatic hydrolysis of **5** with naringinase furnished momordicoside F₂ (**19**).^{3c)} The $^1\text{H-NMR}$ (pyridine- d_5) and $^{13}\text{C-NMR}$ (Table 1) spectra⁷⁾ of **5** showed signals assignable to a β -D-glucopyranosyl moiety [δ 4.98 (d, $J=7.6$ Hz, 1'-H)] together with a momordicoside F₂ moiety [δ 0.98 (d, $J=5.6$ Hz, 21- H_3), 2.31 (br s, 8-H), 3.64 (br s, 3-H), 3.65, 3.71 (ABq, $J=7.9$ Hz, 19- H_2), 5.35 (d, $J=8.5$ Hz, 1'-H), 5.56 (dd, $J=3.3, 9.9$ Hz, 7-H), 5.79 (ddd-like, 23-H), 6.01 (d, $J=15.8$ Hz, 24-H), 6.18 (d, $J=9.9$ Hz, 6-H)]. In the HMBC experiment of **5**, long-range correlations were observed between the 1'-proton of the D-allopyranosyl moiety and the 3-carbon and between the 1''-proton of the D-glu-

Table 1. ^{13}C -NMR Data for Goyaglycosides-a (1), -b (2), -c (3), -d (4), -e (5), -f (6), -g (7), and -h (8) and Goyagenin A (20)

	1	2	3	4	5	6	7	8	20
C- 1	18.7	18.7	18.6	18.7	18.9	18.9	18.7	22.7	17.4
2	27.4	27.4	27.3	27.3	27.6	27.6	27.4	29.6	27.2
3	83.8	83.6	83.6	83.4	85.1	85.3	83.7	87.3	76.2
4	39.2	39.1	39.1	39.0	39.0	39.1	39.1	41.8	39.1
5	85.5	85.6	85.4	85.4	86.0	85.9	85.6	143.4	86.8
6	133.2	133.2	133.1	132.9	134.1	134.1	133.2	118.7	132.8
7	131.6	131.6	131.5	131.3	130.0	130.0	131.6	24.7	131.0
8	42.3	42.3	42.2	42.2	52.3	52.3	42.3	43.9	41.7
9	48.2	48.3	48.1	48.1	45.3	45.3	48.2	34.8	48.3
10	41.7	41.7	41.6	41.6	40.2	40.2	41.7	38.6	40.5
11	23.3	23.4	23.2	23.3	23.8	23.9	23.3	32.6	23.2
12	30.9	30.9	30.9	30.9	31.1	31.2	31.0	30.9	30.6
13	45.3	45.3	45.3	45.3	45.5	45.6	45.4	47.1	45.1
14	48.4	48.4	48.2	48.3	48.9	48.9	48.4	49.2	48.0
15	33.9	33.9	33.8	33.9	33.5	33.5	33.9	35.4	33.5
16	28.2	28.2	28.1	28.1	28.2	28.3	28.2	25.3	28.0
17	50.4	50.4	50.3	50.4	50.5	51.3	50.6	48.2	47.6
18	14.9	14.9	14.8	14.9	15.1	15.0	14.9	15.4	15.2
19	112.4	112.5	112.3	112.2	80.2	80.2	112.5	28.1	28.0
20	36.6	36.6	36.3	36.3	36.5	32.7	36.5	43.7	42.4
21	18.9	18.9	18.8	18.9	19.1	19.4	19.1	15.3	15.2
22	39.6	39.6	39.6	39.6	39.8	43.7	39.9	72.8	72.6
23	124.4	124.4	128.3	128.2	128.4	75.2	128.4	75.2	27.6
24	141.7	141.7	137.6	137.4	138.5	129.3	138.5	217.6	18.0
25	69.7	69.7	74.7	74.7	77.6	132.0	77.6	77.3	74.4
26	30.9	30.8	26.0	26.1	28.7	25.8	28.7	28.1	216.1
27	30.9	30.8	26.4	26.5	27.7	18.2	27.7	28.9	77.8
28	21.2	21.2	21.1	21.2	21.1	21.1	21.2	25.9	27.3
29	24.9	24.9	24.8	24.9	25.6	25.6	24.9	28.5	28.9
30	20.0	20.0	19.9	20.0	20.3	20.3	20.0	18.2	25.5
19-OMe	57.6	57.7	57.5	57.6			57.7		
25-OMe			50.0	50.0					
Glc or All-1'	105.3	102.5	105.2	102.3	103.8	106.6	102.5	106.9	
2'	76.2	73.7	76.1	73.6	73.1	75.8	73.7	75.4	
3'	78.6	71.8	77.8	71.6	72.4	78.3	71.8	78.5	
4'	72.1	69.3	72.0	69.2	69.3	72.0	69.3	71.9	
5'	78.0	76.4	78.5	76.3	76.1	78.3	76.4	77.4	
6'	63.1	63.3	63.0	63.2	63.4	63.1	63.3	70.3	
Glc or All-1''					99.8	101.5	99.8	105.3	
2''					75.3	72.7	75.3	75.3	
3''					78.8	73.2	78.8	78.5	
4''					71.9	69.4	71.9	71.9	
5''					78.0	75.7	78.0	78.6	
6''					63.0	63.3	63.0	62.9	

The spectra were taken in pyridine- d_5 at 68 MHz.

copyranosyl moiety and the 25-carbon. Consequently, the structure of goyaglycoside-e was determined as 25-*O*- β -D-glucopyranosyl-5 β ,19-epoxycucurbita-6,23-diene-3 β ,25-diol 3-*O*- β -D-allopyranoside (5).

Goyaglycoside-f (6) was isolated as a white powder with negative optical rotation ($[\alpha]_D^{27} -51.9^\circ$). In the negative- and positive-ion FAB-MS of 6, quasimolecular ion peaks were observed at m/z 779 ($M-H$) $^-$ and m/z 781 ($M+H$) $^+$ and the molecular formula $C_{42}H_{68}O_{13}$ was determined by high-resolution MS measurement. Acid hydrolysis of 6 with 5% aqueous H_2SO_4 -1,4-dioxane (1 : 1, v/v) furnished D-allose and D-glucose.⁵⁾ Furthermore, a fragment ion peak of 6 was observed at m/z 617 ($M-C_6H_{11}O_5$) $^-$. The 1H -NMR (pyridine- d_5) and ^{13}C -NMR (Table 1) spectra⁷⁾ of 6 showed a β -D-glucopyranosyl moiety [δ 4.87 (d, $J=7.6$ Hz, 1'-H)], a β -D-allopyranosyl moiety [δ 5.34 (d, $J=7.9$ Hz, 1''-H)], and an aglycone moiety [δ 2.31 (br s, 8-H), 3.61, 3.67 (ABq, $J=8.2$ Hz, 19-H₂), 3.69 (br s, 3-H), 5.56 (d-like, 24-H), 5.61

(dd-like, 7-H), 6.19 (d, $J=9.2$ Hz, 6-H)]. The carbon and proton signals due to the tetracyclic carbon skeleton structure (C-1—21, C-28—30) of the aglycone moiety were superimposable on those of 5, whereas the signals due to the side chain structure (C-22—27) were similar to those of protojubilubosides⁹⁾ having the 23-*O*-glycosyl-24-ene structure. The plane structure of the aglycone moiety in 6 was determined by a detailed HMBC experiment. Namely, long-range correlations were observed between the following protons and carbons: 19-H₂ and 5, 8, 9, 10-C; 21-H₃ and 17, 20, 22-C; 26, 27-H₃ and 24, 25-C; 28, 29-H₃ and 3, 4, 5-C; 18-H₃ and 12, 13, 14, 17-C; 30-H₃ and 8, 13, 14, 15-C; 1'-H and 3-C; 1''-H and the 23-C (Fig. 1). The stereostructure of the aglycone moiety was characterized by NOESY experiment, which were observed between the following protons and protons: 28-H₃ and 3-H, 30-H₃; 30-H₃ and 17-H; 19-H₂ and 8-H, 29-H₃; 8-H and 18-H₃ (Fig. 1). Consequently, the structure of goyaglycoside-f was determined to be 23-*O*- β -D-allopyra-




Fig. 1




Fig. 2

nosyl 5 β ,19-epoxycucurbita-6,24-diene-3 β ,23 ξ -diol 3-*O*- β -D-glucopyranoside (**6**).

Goyaglycoside-g (**7**), obtained as a white powder, liberated D-allose and D-glucose by acid hydrolysis. The molecular formula C₄₃H₇₀O₁₄ of **7** was obtained from quasimolecular ion peaks [*m/z* 809 (M-H)⁻ and 833 (M+Na)⁺] in the negative- and positive-ion FAB-MS. Enzymatic hydrolysis of **7** with cellulase furnished goyaglycoside-b (**2**). The ¹H-NMR (pyridine-*d*₅) and ¹³C-NMR (Table 1) spectra⁷ of **7** showed signals due to a goyaglycoside-b moiety [δ 0.83, 0.91, 0.92, 1.44, 1.54, 1.60 (all s, 29, 18, 30, 28, 26, 27-H₃), 1.00 (d, *J*=5.3 Hz, 21-H₃), 3.12 (dd-like, 8-H), 3.50 (s, 19-OMe), 3.69 (br s, 3-H), 4.89 (s, 19-H), 5.43 (d, *J*=7.6 Hz, 1'-H), 5.61 (dd, *J*=3.3, 9.9 Hz, 7-H), 5.79 (ddd, *J*=5.6, 7.9, 15.8 Hz, 23-H), 6.01 (d, *J*=15.8 Hz, 24-H), 6.15 (dd, *J*=2.3, 9.9 Hz, 6-H)] together with an β -D-glucopyranosyl moiety [δ 4.99 (1H, d, *J*=7.9 Hz, 1''-H)]. In the HMBC experiment of **7**, a long-range correlation was observed between the 1''-proton of the glucopyranosyl moiety and the 25-carbon. Consequently, the structure of goyaglycoside-g was determined to be 25-*O*- β -D-glucopyranosyl-19(*R*)-methoxy-5 β ,19-epoxycucurbita-6,23-diene-3 β ,25-diol 3-*O*- β -D-allopyranoside (**7**).⁸

Goyaglycoside-h (**8**) was isolated as a white powder with positive optical rotation ([α]_D²⁴ +0.7°). In the negative- and positive-ion FAB-MS of **8**, quasimolecular ion peaks were observed at *m/z* 813 (M-H)⁻ and *m/z* 837 (M+Na)⁺, and high-resolution MS analysis revealed the molecular formula of **8** to be C₄₂H₇₀O₁₅. By acid hydrolysis with 5% aqueous H₂SO₄-1,4-dioxane (1 : 1, v/v), **8** liberated D-glucose.⁵ Enzymatic hydrolysis of **8** with naringinase furnished a new triterpene aglycone called goyagenin A (**20**), whose molecular

formula C₃₀H₅₀O₅ was determined from the positive-ion FAB-MS [*m/z* 513 (M+Na)⁺] and by high-resolution MS measurement. The IR spectrum of **20** showed absorption bands at 3567 and 1717 cm⁻¹ suggestive of hydroxyl and carbonyl functions. The ¹H-NMR (pyridine-*d*₅) and ¹³C-NMR (Table 1) spectra⁷ of **8** showed signals due to six tertiary methyls [δ 0.80, 0.88, 0.91, 1.06, 1.48, 1.63, 1.72 (all s, 30, 19, 28, 18, 29, 27, 26-H₃)], three methines bearing a hydroxyl group [δ 3.73 (br s, 3-H), 4.81 (dd-like, 22-H), 5.53 (d-like, 23-H)], a secondary methyl [δ 1.50 (d, *J*=6.3 Hz, 21-H₃)], a olefin [δ 5.45 (dd-like, 6-H)], and two β -D-glucopyranosyl moieties [δ 4.80 (d, *J*=7.6 Hz, 1'-H), 5.17 (d, *J*=7.6 Hz, 1''-H)] together with a carbonyl and four quaternary carbons. The proton and carbon signals of **8** in ¹H- and ¹³C-NMR spectra were superimposable on those of a known cucurbitane-type triterpene saponin, momordicoside A (**12**),^{3a} except for those around the 24-position. In the HMBC spectrum of **8**, long-range correlations were observed between the following protons and carbons: Glc-1'-H and 3-C; Glc-1''-H and Glc-6'-C; 26-, 27-H₃ and 24-C. These findings and comparisons of the ¹H- and ¹³C-NMR spectra of **8** with those of known momordicosides³ led us to formulate the structure of **8** as 3,22,23,25-tetrahydroxycucurbit-5-ene-24-one 3-*O*- β -D-glucopyranosyl(1 \rightarrow 6)- β -D-glucopyranoside.

In order to learn the absolute stereostructure of **8**, the aglycone, goyagenin A (**20**) was treated with sodium borohydride (NaBH₄) to furnish 3 β ,22(*S*),23(*R*),24(*R*),25-pentahydroxycucurbit-5-ene (**21**)^{3a} and its 24-diastereomer (**22**) as shown in Fig. 2. On the basis of the evidence, goyaglycoside-h was determined to be 3 β ,22(*S*),23(*R*),25-tetrahydroxycucurbit-5-ene-24-one 3-*O*- β -D-glucopyranosyl(1 \rightarrow 6)- β -D-glucopyranoside.

Table 2. ^{13}C -NMR Data for Goyasaponins I (**9**), II (**10**), and III (**11**), Goyaprosaponin (**24**), and Desacyl-goyasaponin III (**25**)

	9	10	24	11	25		9	10	24		11	25
C-1	38.2	38.2	38.1	38.6	38.7	Gal-1	106.4	106.2	106.3	Xyl-1	105.5	106.2
2	25.1	25.1	24.9	26.5	26.6	2	74.5	74.3	74.4	2	75.1	76.5
3	83.6	83.7	83.5	90.0	89.5	3	74.9	74.9	74.9	3	78.4	78.1
4	55.0	55.0	55.0	39.6	39.6	4	70.2	70.2	70.2	4	71.1	71.1
5	48.6	48.5	48.4	55.8	55.9	5	77.1	78.1	77.1	5	67.2	67.4
6	20.5	20.4	20.4	18.5	18.5	6	62.2	62.2	62.2	Glc-1	104.6	104.7
7	32.6	32.6	32.5	33.2	33.3	Fuc-1	93.8	93.8		2	75.2	74.9
8	40.2	40.2	40.0	39.8	39.8	2	76.7	76.8		3	78.2	78.0
9	47.8	47.8	47.9	48.0	48.1	3	83.7	83.4		4	71.8	71.6
10	36.3	36.3	36.3	37.1	37.0	4	72.6	72.5		5	78.2	78.0
11	23.3	23.3	23.7	23.8	23.8	5	74.4	74.4		6	63.0	62.5
12	122.6	122.6	122.2	122.6	122.6	6	18.9	18.9		Ac-1	170.8	
13	144.1	144.0	144.9	144.9	144.9	Rha-1	100.9	100.9		2	21.6	
14	42.2	42.2	42.2	42.2	42.2	2	71.7	71.7				
15	28.2	28.2	28.3	28.4	28.4	3	72.6	72.6				
16	23.7	23.7	23.8	23.8	23.8	4	84.3	83.9				
17	47.1	47.0	46.6	46.7	46.7	5	68.8	68.7				
18	42.0	42.0	42.0	42.0	42.1	6	18.5	18.5				
19	46.3	46.3	46.5	46.5	46.6	Rha-1'	101.7	101.6				
20	30.8	30.8	30.9	31.0	31.0	2'	72.4	72.4				
21	34.0	34.0	34.2	34.3	34.3	3'	72.9	72.9				
22	32.4	32.4	33.2	33.2	33.3	4'	70.5	70.4				
23	209.6	209.6	209.3	27.8	27.9	5'	73.8	73.8				
24	11.0	11.0	10.9	16.4	16.4	6'	18.4	18.4				
25	15.7	15.7	15.6	15.4	15.5	Xyl-1	107.2	106.4				
26	17.6	17.6	17.3	17.4	17.4	2	76.0	75.0				
27	26.1	26.0	26.2	26.2	26.2	3	78.6	86.9				
28	176.2	176.2	180.1	180.1	180.1	4	70.9	69.0				
29	33.1	33.1	33.3	33.3	33.3	5	67.5	66.8				
30	23.8	23.8	23.8	23.8	23.8	Xyl-1'		105.8				
GlcA-1	103.4	103.4	103.3	104.9	105.0	2'		75.2				
2	82.5	82.3	82.5	78.3	81.6	3'		78.1				
3	77.7	77.7	77.7	75.1	76.1	4'		70.9				
4	72.6	72.6	72.8	78.0	82.0	5'		67.3				
5	77.3	77.4	77.4	76.1	78.4							
6	172.6	172.2	172.2	171.8	172.0							

The spectra were taken in pyridine- d_5 at 125 MHz.

side (**8**).

Structures of Oleanene-Type Triterpene Saponins (9—11) Goyasaponin I (**9**) was obtained as a white powder with negative optical rotation ($[\alpha]_D^{24} -13.5^\circ$). The IR spectrum of **9** showed absorption bands at 3410, 1717, 1684, 1078, and 1046 cm^{-1} due to hydroxyl, carbonyl, and carboxyl functions. In the negative- and positive-ion FAB-MS of **9**, quasi-molecular ion peaks were observed at m/z 1377 ($(\text{M}-\text{H})^-$) and m/z 1401 ($(\text{M}+\text{Na})^+$) and the molecular formula $\text{C}_{65}\text{H}_{102}\text{O}_{31}$ was determined by high-resolution MS measurement. Furthermore, fragment ion peaks were observed at m/z 1231 ($(\text{M}-\text{C}_6\text{H}_{11}\text{O}_4)^-$), 1215 ($(\text{M}-\text{C}_6\text{H}_{11}\text{O}_5)^-$), 1099 ($(\text{M}-\text{C}_{11}\text{H}_{19}\text{O}_8)^-$), 1039 ($(\text{M}-\text{C}_{12}\text{H}_{19}\text{O}_{11})^-$), and 807 ($(\text{M}-\text{C}_{23}\text{H}_{39}\text{O}_{16})^-$) in the negative-ion FAB-MS of **9**. Acid hydrolysis of **9** with 5% aqueous H_2SO_4 -1,4-dioxane (1 : 1, v/v) furnished D-xylose, L-rhamnose, D-fucose, D-galactose, and D-glucuronic acid,⁵ while methanolysis of **9** with 9% HCl-dry methanol liberated gypsogenin (**23**).¹⁰ Alkaline hydrolysis of **9** with 5% aqueous NaOH provided goyaprosaponin (**24**).

By acid hydrolysis with 5% aqueous H_2SO_4 -1,4-dioxane (1 : 1, v/v), goyaprosaponin (**24**) liberated D-glucuronic acid and D-galactose.⁵ The molecular formula $\text{C}_{42}\text{H}_{64}\text{O}_{15}$ of **24** was also determined from the negative- and positive-ion FAB-MS [m/z 807 ($(\text{M}-\text{H})^-$), m/z 831 ($(\text{M}+\text{Na})^+$)] and by high-resolution MS measurement. The ^1H -NMR (pyridine-

d_5) and ^{13}C -NMR (Table 2) spectra⁷ of **24** showed signals due to the gypsogenin moiety [δ 3.26 (dd-like, 18-H), 4.06 (dd-like, 3-H), 5.43 (br s, 12-H), 9.92 (s, 23-H)] and the disaccharide moiety consisted of a β -D-glucopyranosiduronic acid [δ 4.90 (d, $J=7.3$ Hz, GlcA-1-H)] and a β -D-galactopyranosyl [δ 5.18 (d, $J=7.6$ Hz, Gal-1-H)] part. The disaccharide structure bonding to the 3-position of **24** was determined by HMBC experiment. Thus, long-range correlations were observed between the 1-proton of the glucuronic acid part and the 3-carbon of the gypsogenin part and between the 1-proton of the galactopyranosyl moiety and the 2-carbon of the glucuronic acid part. Based on this evidence, the structure of goyaprosaponin (**24**) was elucidated.

The ^1H -NMR (pyridine- d_5) and ^{13}C -NMR (Table 2) spectra⁷ of **9** indicated the presence of a β -D-fucopyranosyl moiety [δ 1.53 (d, $J=6.1$ Hz, Fuc-6- H_3), 6.27 (d, $J=5.5$ Hz, Fuc-1-H)], two α -L-rhamnopyranosyl moiety [δ 1.61 (d, $J=6.1$ Hz, Rha-6'- H_3), 1.71 (d, $J=5.2$ Hz, Rha-6- H_3), 5.65 (br s, Rha-1'-H), 5.74 (br s, Rha-1-H)], and a β -D-xylopyranosyl moiety [δ 5.05 (1H, d, $J=7.3$ Hz, Xyl-1-H)] together with a goyaprosaponin moiety [δ 3.11 (dd, $J=3.0$, 13.3 Hz, 18-H), 4.04 (dd-like, 3-H), 5.38 (br s, 12-H), 9.92 (s, 23-H), 4.89 (d, $J=7.3$ Hz, GlcA-1-H), 5.18 (d, $J=7.6$ Hz, Gal-1-H)]. The tetrasaccharide structure bonding to the 28-carboxyl group of gypsogenin in **9** was characterized by a HMBC experiment.

Namely, long-range correlations were observed between the following protons and carbons [Fuc-1-H and 28-C; Rha-1-H and Fuc-2-C; Rha-1'-H and Fuc-3-C; Xyl-1-H and Rha-4-C]. Consequently, the structure of goyasaponin I has been elucidated as 28-*O*- β -D-xylopyranosyl(1 \rightarrow 4)- α -L-rhamnopyranosyl(1 \rightarrow 2)-[α -L-rhamnopyranosyl(1 \rightarrow 3)]- β -D-fucopyranosyl gypsogenin 3-*O*- β -D-galactopyranosyl(1 \rightarrow 2)- β -D-glucopyranosiduronic acid (**9**).

Goyasaponin II (**10**), isolated as a white powder, furnished goyasaponin (**24**) upon alkaline hydrolysis. The molecular formula $C_{70}H_{110}O_{35}$ was determined from the negative- [m/z 1509 (M-H)⁻] and positive- [m/z 1533 (M+Na)⁺] ion FAB-MS and by high-resolution MS measurement. Furthermore, fragment ion peaks were observed at m/z 1363 (M-C₆H₁₁O₄)⁻, 1347 (M-C₆H₁₁O₅)⁻, 1245 (M-C₁₀H₁₇O₈)⁻, 1171 (M-C₁₂H₁₉O₁₁)⁻, and 1099 (M-C₁₆H₂₇O₁₂)⁻ were observed in the negative-ion FAB-MS of **10**. Acid hydrolysis of **10** with 5% aqueous H₂SO₄-1,4-dioxane (1:1, v/v) furnished D-xylose, L-rhamnose, D-fucose, D-galactose, and D-glucuronic acid.⁵⁾ The ¹H-NMR (pyridine-*d*₅) and ¹³C-NMR (Table 2) spectra⁷⁾ of **10** showed signals assignable to a β -D-glucopyranosiduronic acid moiety [δ 4.89 (d, $J=7.3$ Hz, GlcA-1-H)], a β -D-galactopyranosyl moiety [δ 5.20 (d, $J=7.3$, Gal-1-H)], a β -D-fucopyranosyl moiety [δ 1.54 (d, $J=5.8$ Hz, Fuc-6-H₃), 6.28 (d, $J=5.5$ Hz, Fuc-1-H)], two α -L-rhamnopyranosyl moieties [δ 1.61 (d, $J=6.1$ Hz, Rha-6'-H₃), 1.68 (d, $J=5.5$ Hz, Rha-6-H₃), 5.65 (brs, Rha-1'-H), 5.73 (brs, Rha-1-H)], two β -D-xylopyranosyl moieties [δ 5.07 (d, $J=7.0$ Hz, Xyl-1-H), 5.18 (d, $J=7.3$ Hz, Xyl-1'-H)], and a gypsogenin moiety [δ 3.11 (dd-like, 18-H), 4.04 (dd, $J=5.8$, 15.0 Hz, 3-H), 5.44 (brs, 12-H), 9.93 (s, 23-H)]. The oligoglycoside structure of **10** was characterized by a HMBC experiment, which showed long-range correlations between the following protons and carbons: GlcA-1-H and 3-C, Gal-1-H and GlcA-2-C, Fuc-1-H and 28-C, Rha-1-H and Fuc-2-C, Rha-1'-H and Fuc-3-C, Xyl-1-H and Rha-4-C, Xyl-1'-H and Xyl-3-C. The carbon signals in the ¹³C-NMR spectrum of **10** were very similar to those of **9**, except for the signals due to an additional xylopyranosyl moiety of **10**. Consequently, goyasaponin II was determined to be 28-*O*- β -D-xylopyranosyl(1 \rightarrow 3)- β -D-xylopyranosyl(1 \rightarrow 4)- α -L-rhamnopyranosyl(1 \rightarrow 2)-[α -L-rhamnopyranosyl(1 \rightarrow 3)]- β -D-fucopyranosyl gypsogenin 3-*O*- β -D-galactopyranosyl(1 \rightarrow 2)- β -D-glucopyranosiduronic acid (**10**).

Goyasaponin III (**11**), isolated as a white powder with negative optical rotation ($[\alpha]_D^{24} -1.9^\circ$), liberated D-glucuronic acid, D-xylose, and D-glucose on acid hydrolysis,⁵⁾ and its IR spectrum showed absorption bands due to hydroxyl, carboxyl, and carbonyl functions. Here again, the molecular formula $C_{49}H_{76}O_{19}$ of **11** was identified from the negative- and positive-ion FAB-MS [quasimolecular ion peaks: m/z 967 (M-H)⁻, m/z 991 (M+Na)⁺] and by high-resolution MS measurement.

Treatment of **11** with 1% sodium methoxide in methanol at room temperature furnished desacyl-goyasaponin III (**25**), whose molecular formula $C_{47}H_{74}O_{18}$ was determined by high-resolution MS measurement of the quasimolecular ion peaks in the negative- [m/z 925 (M-H)⁻] and positive- [m/z 949 (M+Na)⁺] ion FAB-MS. Acid hydrolysis of **25** with 5% aqueous H₂SO₄-1,4-dioxane (1:1, v/v) liberated oleanolic acid, D-glucuronic acid, D-xylose, and D-glucose.⁵⁾ The ¹H-

NMR (pyridine-*d*₅) and ¹³C-NMR (Table 2) spectra⁷⁾ of **25** showed signals assignable to an oleanolic acid part [δ 3.25 (dd, $J=4.0$, 11.6 Hz, 3-H), 3.29 (dd, $J=3.7$, 13.7 Hz, 18-H), 5.45 (brs, 12-H)], a β -D-glucopyranosiduronic acid part [δ 5.27 (d, $J=7.3$ Hz, GlcA-1-H)], a β -D-xylopyranosyl part [δ 4.94 (d, $J=7.6$ Hz, Xyl-1-H)], and a β -D-glucopyranosyl part [δ 5.15 (d, $J=7.6$ Hz, Glc-1-H)]. The triglycoside structure bonding to the 3-hydroxyl group of an oleanolic acid moiety in **11** was characterized by a HMBC experiment. Namely, long-range correlations were observed between the following protons and carbons: GlcA-1-H and 3-C; Xyl-1-H and GlcA-2-C; Glc-1-H and GlcA-4-C; GlcA-3-H and Ac-1-C.

The ¹H-NMR (pyridine-*d*₅) and ¹³C-NMR (Table 2) spectra⁷⁾ of **11** showed signals assignable to an acetyl group [δ 2.45 (3H, s, Ac-2)] together with the desacyl-goyasaponin III moiety. Comparison of the ¹H- and ¹³C-NMR data for **11** with those for **25** revealed an acylation shift around the 3-position of the D-glucopyranosiduronic acid moiety in the triglycoside part of **11**. In the HMBC experiment of **11**, a long-range correlation was observed between the 3-proton of the D-glucopyranosiduronic acid moiety and the acetyl carbonyl carbon. Consequently, the structure of goyasaponin III has been elucidated as oleanolic acid 3-*O*-[β -D-xylopyranosyl(1 \rightarrow 2)][β -D-glucopyranosyl(1 \rightarrow 4)]-3'-*O*-acetyl- β -D-glucopyranosiduronic acid (**11**).

Experimental

The instruments used to obtain physical data and the experimental conditions for chromatography were described previously.¹⁾

Isolation of Goyaglycosides-a (1), -b (2), -c (3), -d (4), -e (5), -f (6), -g (7), and -h (8), Goyasaponins I (9), II (10), and III (11) and Five Known Glycosides (12–16) from the Fresh Fruit of *M. charantia* L. The fresh whole fruit of *M. charantia* L. (36.9 kg, cultivated in Okinawa prefecture, Japan), which included the immature seeds, was cut and extracted three times with MeOH under reflux. Evaporation of the solvent under reduced pressure provided the MeOH extract (846.0 g, 2.3%), and the extract (828.0 g) was partitioned into the AcOEt-H₂O (1:1) mixture. The water phase was further extracted with the *n*-BuOH. Removal of the solvent under reduced pressure from the AcOEt- and *n*-BuOH-soluble portions yielded 64.5 g (0.17%) and 98.3 g (0.27%) of residues, respectively. The *n*-BuOH-soluble portion (88.3 g) was subjected to normal-phase silica gel column chromatography [BW-200 (Fuji Silysia Co., Ltd., 4.5 kg), CHCl₃-MeOH-H₂O (15:3:1, lower layer \rightarrow 10:3:1, lower layer \rightarrow 65:35:10, lower layer \rightarrow 6:4:1, v/v) \rightarrow MeOH] to give five fractions [Fr. 1 (2.5 g), Fr. 2 (4.0 g), Fr. 3 (6.1 g), Fr. 4 (21.4 g), Fr. 5 (50.2 g)].

Fraction 1 (2.5 g) was subjected to normal-phase silica gel column chromatography [140 g, CHCl₃-MeOH-H₂O (30:3:1, lower layer \rightarrow 20:3:1, lower layer, v/v) \rightarrow MeOH] to give Fr. 1-1 (218.9 mg), Fr. 1-2 (1.5 g), Fr. 1-3 (553.9 mg), Fr. 1-4 (187.3 mg). Fraction 1-2 (1.5 g) was separated by reversed-phase silica gel column chromatography [Chromatorex ODS DM1020T (Fuji Silysia Chemical Ltd., 30 g), MeOH-H₂O (70:30 \rightarrow 80:20 \rightarrow 90:10, v/v)] and HPLC [YMC-Pack ODS-A (YMC Co., Ltd.), 1) MeOH-H₂O (85:15, v/v), 2) CH₃CN-H₂O (50:50, v/v)] to give goyaglycosides-a (**1**, 28.5 mg, 0.00008%) and -b (**2**, 20.0 mg, 0.00005%) and momordicoside I (**15**, 23.0 mg, 0.00006%). Fraction 1-3 (553.9 mg) was separated by reversed-phase silica gel column chromatography [11 g, MeOH-H₂O (50:50 \rightarrow 75:25 \rightarrow 85:15, v/v) \rightarrow MeOH] and HPLC [CH₃CN-H₂O (50:50, v/v)] to give momordicoside K (**16**, 9.9 mg, 0.00003%).

Fraction 2 (2.5 g) was subjected to reversed-phase silica gel column chromatography [100 g, MeOH-H₂O (50:50 \rightarrow 85:15 \rightarrow 90:10 \rightarrow 95:5, v/v) \rightarrow MeOH] to give Fr. 2-1 (2.0 g), Fr. 2-2 (193.8 mg), Fr. 2-3 (133.9 mg), Fr. 2-4 (706.2 mg), Fr. 2-5 (415.6 mg), Fr. 2-6 (234.3 mg), Fr. 2-7 (185.9 mg). Fraction 2-4 was purified by HPLC [MeOH-H₂O (85:15, 70:30, v/v), CH₃CN-H₂O (35:65, v/v)] to give goyaglycosides-e (**5**, 37.2 mg, 0.00010%), -f (**6**, 32.0 mg, 0.00009%), and -h (**8**, 27.7 mg, 0.00008%).

Fraction 3 was separated by normal-phase silica gel column chromatography [305 g, CHCl₃-MeOH-H₂O (20:3:1, lower layer \rightarrow 15:3:1, lower layer \rightarrow 10:3:1, lower layer \rightarrow 7:3:1, lower layer, v/v) \rightarrow MeOH] to give Fr.

3-1 (132.0 mg), Fr. 3-2 (359.9 mg), Fr. 3-3 (609.5 mg), Fr. 3-4 (327.2 mg), Fr. 3-5 (597.3 mg), Fr. 3-6 (3.8 g). Fraction 3-2 (359.9 mg) was purified by HPLC [1] MeOH-H₂O (85:15, v/v), 2) CH₃CN-H₂O (75:25, v/v)] to give goglyglycoside-d (**4**, 29.9 mg, 0.00008%). Fraction 3-3 (609.5 mg) was purified by HPLC [MeOH-H₂O (85:15, v/v)] to give goglyglycoside-c (**3**, 24.2 mg, 0.00007%) and momordicoside F₁ (**14**, 40.5 mg, 0.00011%).

Fraction 4 (21.4 g) was separated by reversed-phase silica gel column chromatography [520 g, MeOH-H₂O (50:50→65:35→80:20, v/v)→MeOH] and HPLC [MeOH-1% aq. AcOH (65:45, v/v)] to give goglyglycoside-g (**7**, 23.8 mg, 0.00006%) and momordicosides A (**12**, 473.2 mg, 0.0013%) and C (**13**, 59.3 mg, 0.00016%).

Fraction 5 (49.0 g) was subjected to reversed-phase silica gel column chromatography [900 g, MeOH-H₂O (50:50→80:20, v/v)→MeOH] to give Fr. 5-1 (35.6 g), Fr. 5-2 (1.2 g), Fr. 5-3 (442.9 mg), Fr. 5-4 (2.4 g), Fr. 5-5 (2.5 g). Fraction 5-4 (327.3 mg) was purified by HPLC [MeOH-1% aq. AcOH (80:20, v/v)] to give goyasaponins I (**9**, 37.4 mg, 0.00010%), II (**10**, 101.1 mg, 0.00027%). Fraction 5-5 (2.5 g) was separated by reversed-phase silica gel column chromatography [MeOH-H₂O (70:30→80:20, v/v)→MeOH] and HPLC [MeOH-1% aq. AcOH (80:20, v/v)] to give goyasaponin III (**11**, 32.6 mg, 0.00009%).

The known compounds (**12**–**16**) were identified by comparison of their physical data ($[\alpha]_D^{25}$, IR, ¹H-NMR, ¹³C-NMR) with reported values.³⁾

Goglyglycoside-a (1): A white powder, $[\alpha]_D^{25}$ -101.4° (*c*=0.5, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₃₇H₆₁O₉ (M+H)⁺: 649.4316. Found: 649.4307. IR (KBr): 3423, 1080 cm⁻¹. ¹H-NMR (270 MHz, pyridine-*d*₅) δ: 0.86, 0.89, 0.90, 1.47 (3H each, all s, 29, 30, 18, 28-H₃), 0.97 (3H, d, *J*=5.3 Hz, 21-H₃), 1.54 (6H, s, 26, 27-H₃), 3.12 (1H, dd-like, 8-H), 3.44 (3H, s, 19-OMe), 3.73 (1H, brs, 3-H), 4.84 (1H, s, 19-H), 4.95 (1H, d, *J*=7.6 Hz, 1'-H), 5.62 (1H, dd, *J*=3.6, 9.6 Hz, 7-H), 5.92 (2H, m, 23, 24-H), 6.16 (1H, dd, *J*=2.0, 9.6 Hz, 6-H). ¹³C-NMR (68 MHz, pyridine-*d*₅) δ: given in Table 1. Negative-ion FAB-MS: *m/z* 647 (M-H)⁻, 617 (M-CH₃O)⁻, 455 (M-CH₃O-C₆H₁₀O₅)⁻. Positive-ion FAB-MS: *m/z* 649 (M+H)⁺.

Goglyglycoside-b (2): A white powder, $[\alpha]_D^{23}$ -110.7° (*c*=0.5, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₃₇H₆₁O₉ (M+H)⁺: 649.4316. Found: 649.4320. IR (KBr): 3428, 1086, 1032 cm⁻¹. ¹H-NMR (270 MHz, pyridine-*d*₅) δ: 0.83, 0.89, 0.90, 1.44 (3H each, all s, 29, 30, 18, 28-H₃), 0.98 (3H, d, *J*=5.3 Hz, 21-H₃), 1.54 (6H, s, 26, 27-H₃), 3.13 (1H, dd-like, 8-H), 3.50 (3H, s, 19-OMe), 3.70 (1H, brs, 3-H), 4.88 (1H, s, 19-H), 5.44 (1H, d, *J*=7.6 Hz, 1'-H), 5.61 (1H, dd, *J*=3.3, 9.6 Hz, 7-H), 5.92 (2H, m, 23, 24-H), 6.15 (1H, dd, *J*=2.0, 9.6 Hz, 6-H). ¹³C-NMR (68 MHz, pyridine-*d*₅) δ: given in Table 1. Negative-ion FAB-MS: *m/z* 647 (M-H)⁻, 455 (M-CH₃O-C₆H₁₀O₅)⁻. Positive-ion FAB-MS: *m/z* 649 (M+H)⁺.

Goglyglycoside-c (3): A white powder, $[\alpha]_D^{26}$ -110.8° (*c*=0.5, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₃₈H₆₂O₉Na (M+Na)⁺: 685.4292. Found: 685.4296. IR (KBr): 3410, 1078 cm⁻¹. ¹H-NMR (270 MHz, pyridine-*d*₅) δ: 0.86, 1.48 (3H each, both s, 29, 28-H₃), 0.92, 1.33 (6H each, all s, 18, 30, 26, 27-H₃), 3.13 (1H, dd-like, 8-H), 3.22, 3.44 (3H each, both s, 25, 19-OMe), 3.73 (1H, brs, 3-H), 4.85 (1H, s, 19-H), 4.95 (1H, d, *J*=7.6 Hz, 1'-H), 5.55 (1H, d, *J*=15.8 Hz, 24-H), 5.65 (2H, m, 7, 23-H), 6.17 (1H, dd, *J*=1.7, 9.6 Hz, 6-H). ¹³C-NMR (68 MHz, pyridine-*d*₅) δ: given in Table 1. Negative-ion FAB-MS: *m/z* 661 (M-H)⁻, 647 (M-CH₃)⁻, 499 (M-C₆H₁₁O₅)⁻. Positive-ion FAB-MS: *m/z* 685 (M+Na)⁺.

Goglyglycoside-d (4): A white powder, $[\alpha]_D^{26}$ -141.1° (*c*=0.1, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₃₈H₆₂O₉Na (M+Na)⁺: 685.4292. Found: 685.4298. IR (KBr): 3434, 1082, 1034 cm⁻¹. ¹H-NMR (270 MHz, pyridine-*d*₅) δ: 0.83, 1.44 (3H each, both s, 29, 28-H₃), 0.93, 1.33 (6H each, both s, 18, 30, 26, 27-H₃), 0.99 (3H, d, *J*=5.4 Hz, 21-H₃), 3.14 (1H, dd-like, 8-H), 3.22, 3.50 (3H each, both s, 25, 19-OMe), 3.69 (1H, brs, 3-H), 4.89 (1H, s, 19-H), 5.43 (1H, d, *J*=7.7 Hz, 1'-H), 5.55 (1H, d, *J*=15.8 Hz, 24-H), 5.62 (1H, dd, *J*=3.7, 9.7 Hz, 7-H), 5.66 (1H, ddd, *J*=5.6, 8.6, 15.8 Hz, 23-H), 6.15 (1H, dd, *J*=1.8, 9.8 Hz, 6-H). ¹³C-NMR (68 MHz, pyridine-*d*₅) δ: given in Table 1. Negative-ion FAB-MS: *m/z* 661 (M-H)⁻, 499 (M-C₆H₁₁O₅)⁻. Positive-ion FAB-MS: *m/z* 685 (M+Na)⁺.

Goglyglycoside-e (5): A white powder, $[\alpha]_D^{28}$ -75.6° (*c*=0.7, EtOH). High-resolution positive-ion FAB-MS: Calcd for C₄₂H₆₉O₁₃ (M+H)⁺: 781.4739. Found: 781.4744. IR (KBr): 3410, 1082, 1032 cm⁻¹. ¹H-NMR (270 MHz, pyridine-*d*₅) δ: 0.77, 0.89, 0.90, 1.45, 1.54, 1.60 (3H each, all s, 18, 30, 29, 28, 26, 27-H₃), 0.98 (3H, d, *J*=5.6 Hz, 21-H₃), 2.31 (1H, brs, 8-H), 3.64 (1H, brs, 3-H), 3.65, 3.71 (1H each, ABq, *J*=7.9 Hz, 19-H₂), 4.98 (1H, d, *J*=7.6 Hz, 1'-H), 5.35 (1H, d, *J*=8.5 Hz, 1'-H), 5.56 (1H, dd, *J*=3.3, 9.9 Hz, 7-H), 5.79 (1H, ddd-like, 23-H), 6.01 (1H, d, *J*=15.8 Hz, 24-H), 6.18 (1H, d, *J*=9.9 Hz, 6-H). ¹³C-NMR (68 MHz, pyridine-*d*₅) δ: given in Table 1. Negative-ion FAB-MS: *m/z* 779 (M-H)⁻, 617 (M-C₆H₁₁O₅)⁻. Positive-

ion FAB-MS: *m/z* 781 (M+H)⁺.

Goglyglycoside-f (6): A white powder, $[\alpha]_D^{27}$ -51.9° (*c*=0.5, EtOH). High-resolution positive-ion FAB-MS: Calcd for C₄₂H₆₉O₁₃ (M+H)⁺: 781.4739. Found: 781.4733. IR (KBr): 3410, 1082, 1032 cm⁻¹. ¹H-NMR (270 MHz, pyridine-*d*₅) δ: 0.79, 0.89, 0.92, 1.49, 1.68, 1.71 (3H each, all s, 18, 30, 29, 28, 26, 27-H₃), 1.12 (3H, d, *J*=6.3 Hz, 21-H₃), 2.31 (1H, brs, 8-H), 3.61, 3.67 (1H each, ABq, *J*=8.2 Hz, 19-H₂), 3.69 (1H, brs, 3-H), 4.87 (1H, d, *J*=7.6 Hz, 1'-H), 5.34 (1H, d, *J*=7.9 Hz, 1'-H), 5.56 (1H, d-like, 24-H), 5.61 (1H, dd-like, 7-H), 6.19 (1H, d, *J*=9.2 Hz, 6-H). ¹³C-NMR (68 MHz, pyridine-*d*₅) δ: given in Table 1. Negative-ion FAB-MS: *m/z* 779 (M-H)⁻, 617 (M-C₆H₁₁O₅)⁻. Positive-ion FAB-MS: *m/z* 781 (M+H)⁺.

Goglyglycoside-g (7): A white powder, $[\alpha]_D^{27}$ -79.2° (*c*=0.5, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₄₃H₇₀O₁₄Na (M+Na)⁺: 833.4663. Found: 833.4695. IR (KBr): 3434, 1655, 1080, 1034 cm⁻¹. ¹H-NMR (270 MHz, pyridine-*d*₅) δ: 0.83, 0.91, 0.92, 1.44, 1.54, 1.60 (3H each, all s, 29, 18, 30, 28, 26, 27-H₃), 1.00 (3H, d, *J*=5.3 Hz, 21-H₃), 3.12 (1H, dd-like, 8-H), 3.50 (3H, s, 19-OMe), 3.69 (1H, brs, 3-H), 4.89 (1H, s, 19-H), 4.99 (1H, d, *J*=7.9 Hz, 1'-H), 5.43 (1H, d, *J*=7.6 Hz, 1'-H), 5.61 (1H, dd, *J*=3.3, 9.9 Hz, 7-H), 5.79 (1H, ddd, *J*=5.6, 7.9, 15.8 Hz, 23-H), 6.01 (1H, d, *J*=15.8 Hz, 24-H), 6.15 (1H, dd, *J*=2.3, 9.9 Hz, 6-H). ¹³C-NMR (68 MHz, pyridine-*d*₅) δ: given in Table 1. Negative-ion FAB-MS: *m/z* 809 (M-H)⁻, 647 (M-C₆H₁₁O₅)⁻. Positive-ion FAB-MS: *m/z* 833 (M+Na)⁺.

Goglyglycoside-h (8): A white powder, $[\alpha]_D^{24}$ +0.7° (*c*=0.5, pyridine). High-resolution positive-ion FAB-MS: Calcd for C₄₂H₇₀O₁₅Na (M+Na)⁺: 837.4612. Found: 837.4623. IR (KBr): 3432, 1717, 1076, 1038 cm⁻¹. ¹H-NMR (270 MHz, pyridine-*d*₅) δ: 0.80, 0.88, 0.91, 1.06, 1.48, 1.63, 1.72 (3H each, all s, 30, 19, 28, 18, 29, 27, 26-H₃), 1.50 (3H, d, *J*=6.3 Hz, 21-H₃), 1.65 (1H, brs, 8-H), 3.73 (1H, brs, 3-H), 4.80 (1H, d, *J*=7.6 Hz, 1'-H), 4.81 (1H, dd-like, 22-H), 5.17 (1H, d, *J*=7.6 Hz, 1'-H), 5.45 (1H, dd-like, 6-H), 5.53 (1H, d-like, 23-H). ¹³C-NMR (68 MHz, pyridine-*d*₅) δ: given in Table 1. Negative-ion FAB-MS: *m/z* 813 (M-H)⁻, 491 (M-C₁₂H₂₁O₁₀)⁻. Positive-ion FAB-MS: *m/z* 837 (M+Na)⁺.

Goyasaponin I (9): A white powder, $[\alpha]_D^{24}$ -13.5° (*c*=0.5, pyridine). High-resolution positive-ion FAB-MS: Calcd for C₆₅H₁₀₂O₃₁Na (M+Na)⁺: 1401.6303. Found: 1401.6290. IR (KBr): 3410, 1717, 1684, 1078, 1046 cm⁻¹. ¹H-NMR (500 MHz, pyridine-*d*₅) δ: 0.81, 0.90, 0.96, 0.98, 1.21, 1.41 (3H each, all s, 25, 29, 26, 30, 27, 24-H₃), 1.53 (3H, d, *J*=6.1 Hz, Fuc-6-H₃), 1.61 (3H, d, *J*=6.1 Hz, Rha-6'-H₃), 1.71 (3H, d, *J*=5.2 Hz, Rha-6-H₃), 3.11 (1H, dd, *J*=3.0, 13.3 Hz, 18-H), 4.04 (1H, dd-like, 3-H), 4.89 (1H, d, *J*=7.3 Hz, GlcA-1-H), 5.05 (1H, d, *J*=7.3 Hz, Xyl-1-H), 5.18 (1H, d, *J*=7.6 Hz, Gal-1-H), 5.38 (1H, brs, 12-H), 5.65 (1H, brs, Rha-1'-H), 5.74 (1H, brs, Rha-1-H), 6.27 (1H, d, *J*=5.5 Hz, Fuc-1-H), 9.92 (1H, s, 23-H). ¹³C-NMR (125 MHz, pyridine-*d*₅) δ: given in Table 2. Negative-ion FAB-MS: *m/z* 1377 (M-H)⁻, 1231 (M-C₆H₁₁O₄)⁻, 1215 (M-C₆H₁₁O₅)⁻, 1099 (M-C₁₁H₁₉O₈)⁻, 1039 (M-C₁₂H₁₉O₁₁)⁻, 807 (M-C₂₃H₃₉O₁₆)⁻. Positive-ion FAB-MS: *m/z* 1401 (M+Na)⁺.

Goyasaponin II (10): A white powder, $[\alpha]_D^{24}$ -18.5° (*c*=1.0, pyridine). High-resolution positive-ion FAB-MS: Calcd for C₇₀H₁₁₀O₃₅Na (M+Na)⁺: 1533.6725. Found: 1533.6735. IR (KBr): 3432, 1726, 1655, 1080, 1047 cm⁻¹. ¹H-NMR (500 MHz, pyridine-*d*₅) δ: 0.81, 0.90, 0.96, 0.98, 1.21, 1.41 (3H each, all s, 25, 29, 26, 30, 27, 24-H₃), 1.54 (3H, d, *J*=5.8 Hz, Fuc-6-H₃), 1.61 (3H, d, *J*=6.1 Hz, Rha-6'-H₃), 1.68 (3H, d, *J*=5.5 Hz, Rha-6-H₃), 3.11 (1H, dd-like, 18-H), 4.04 (1H, dd, *J*=5.8, 15.0 Hz, 3-H), 4.89 (1H, d, *J*=7.3 Hz, GlcA-1-H), 5.07 (1H, d, *J*=7.0 Hz, Xyl-1-H), 5.18 (1H, d, *J*=7.3 Hz, Xyl-1'-H), 5.20 (1H, d, *J*=7.3, Gal-1-H), 5.44 (1H, brs, 12-H), 5.65 (1H, brs, Rha-1'-H), 5.73 (1H, brs, Rha-1-H), 6.28 (1H, d, *J*=5.5 Hz, Fuc-1-H), 9.93 (1H, s, 23-H). ¹³C-NMR (pyridine-*d*₅, 125 MHz) δ: given in Table 2. Negative-ion FAB-MS: *m/z* 1509 (M-H)⁻, 1363 (M-C₆H₁₁O₄)⁻, 1347 (M-C₆H₁₁O₅)⁻, 1245 (M-C₁₀H₁₇O₈)⁻, 1171 (M-C₁₂H₁₉O₁₁)⁻, 1099 (M-C₁₆H₂₇O₁₂)⁻. Positive-ion FAB-MS: *m/z* 1533 (M+Na)⁺.

Goyasaponin III (11): A white powder, $[\alpha]_D^{24}$ -1.9° (*c*=0.5, pyridine). High-resolution positive-ion FAB-MS: Calcd for C₄₉H₇₆O₁₉Na (M+Na)⁺: 991.4879. Found: 991.4882. IR (KBr): 3422, 1734, 1715, 1076, 1048 cm⁻¹. ¹H-NMR (500 MHz, pyridine-*d*₅) δ: 0.80, 0.95, 0.97, 1.00, 1.03, 1.14, 1.30 (3H each, all s, 25, 29, 26, 30, 24, 23, 27-H₃), 2.45 (3H, s, Ac), 3.18 (1H, dd, *J*=4.3, 11.9 Hz, 3-H), 3.27 (1H, dd, *J*=4.6, 14.0 Hz, 18-H), 4.90 (1H, d, *J*=7.3 Hz, GlcA-1-H), 4.97 (1H, d, *J*=7.3 Hz, Xyl-1-H), 5.20 (1H, d, *J*=7.6 Hz, Glc-1-H), 5.44 (1H, brs, 12-H). ¹³C-NMR (125 MHz, pyridine-*d*₅) δ: given in Table 2. Negative-ion FAB-MS: *m/z* 967 (M-H)⁻, 925 (M-C₂H₃O)⁻, 835 (M-C₆H₁₁O₄)⁻, 805 (M-C₆H₁₁O₅)⁻, 455 (M-C₁₉H₂₉O₁₆)⁻. Positive-ion FAB-MS: *m/z* 991 (M+Na)⁺.

Acid Hydrolysis of Goglyglycosides (1–8), Goyasaponins (9–11), 24, and 25 A solution of 1–11, 24 and 25 (3 mg each) was heated under reflux for 1 h. After cooling, the reaction mixture was neutralized with Amber-

lite IRA-400 (OH⁻ form) and the resin was removed by filtration. After removal of the solvent from the filtrate *in vacuo*, the residue was transferred to a Sep-Pak C18 cartridge with H₂O and MeOH. The H₂O eluate was concentrated and the residue was treated with L-cysteine methyl ester hydrochloride (4 mg) in pyridine (0.5 ml) at 60 °C for 1 h. After reaction, the solution was treated with *N,O*-bis(trimethylsilyl)trifluoroacetamide (0.2 ml) at 60 °C for 1 h. The supernatant was then subjected to GLC analysis to identify the derivatives of D-glucose (i) from **1**, **3**, **5**, **6**, **7**, **8**, **11**, **25**; D-allose (ii) from **2**, **4**, **5**, **6**, **7**; D-glucuronic acid (iii) from **9**, **10**, **11**, **24**, **25**; D-galactose (iv) from **9**, **10**, **24**; D-fucose (v) from **9**, **10**; L-rhamnose (vi) from **9**, **10**; D-xylose (vii) from **9**, **10**, **11**, **25**; GLC conditions: column: Supelco STBTM-1, 30 m × 0.25 mm (i.d.) capillary column, column temperature: 230 °C, He flow rate: 15 ml/min, *t_R*: i: 24.2 min, ii: 27.0 min, i: 24.4 min, ii: 25.5 min, iii: 17.2 min, iv: 15.4 min, v: 13.8 min.

Enzymatic Hydrolysis of Goyaglycosides-a (1) and -c (3) A solution of **1** (9.0 mg) or **3** (9.9 mg) in 0.1 M acetate buffer (pH 4.0, 3 ml) was treated with naringinase (Sigma Chemical Co., 30 mg) and was stirred at 40 °C for 10 days. After addition of EtOH to the reaction mixture, the solvent was removed *in vacuo*. The crude product was purified by reversed-phase (2 g, H₂O→MeOH) and normal-phase silica gel column chromatography [1 g, *n*-hexane-AcOEt (3:1, v/v)] to give 19(*R*)-methoxy-5β,19-epoxycucurbita-6,23-diene-3β,25-diol (**17**, 1.6 mg, 23.7%) or 19(*R*),25-dimethoxy-5β,19-epoxycucurbita-6,23-diene-3β-ol (**18**, 2.3 mg, 30.8%), which were identified by comparison with reported values⁶¹ (¹H-NMR, IR, [α]_D).

Enzymatic Hydrolysis of Goyaglycoside-e (5) A solution of **5** (9.9 mg) in 0.1 M acetate buffer (pH 4.0, 3 ml) was treated with naringinase (Sigma Chemical Co., 30 mg) and was stirred at 40 °C for 24 h. After addition of EtOH to the reaction mixture, the solvent was removed *in vacuo*. The crude product was purified by reversed- (2 g, H₂O→MeOH) and normal-phase silica gel column chromatography [1 g, CHCl₃-MeOH-H₂O (30:3:1, lower layer, v/v)] to give momordicoside F₂ (**19**, 3.0 mg, 38.1%), which was identified by a comparison with reported values^{3(c)} (¹H-NMR, IR, [α]_D).

Enzymatic Hydrolysis of Goyaglycoside-g (7) A solution of **7** (0.9 mg) in 0.1 M acetate buffer (pH 5.0, 2 ml) was treated with cellulase (Sigma Chemical Co., 10 mg) and was stirred at 37 °C for 10 days. After addition of EtOH to the reaction mixture, the solvent was removed *in vacuo*. The crude product was purified by reversed-phase (2 g, H₂O→MeOH) and normal-phase silica gel column chromatography [1 g, CHCl₃-MeOH-H₂O (7:3:1, lower layer, v/v)] to give goyaglycoside-b (**2**, 0.4 mg, 55.5%), which was identified by comparison with an authentic natural sample (¹H-NMR, IR, [α]_D).

Enzymatic Hydrolysis of Goyaglycoside-h (8) A solution of **8** (9.9 mg) in 0.1 M acetate buffer (pH 4.0, 3 ml) was treated with naringinase (Sigma Chemical Co., 30 mg) and was stirred at 40 °C for 24 h. After addition of EtOH to the reaction mixture, the solvent was removed *in vacuo*. The crude product was purified by reversed-phase (2 g, H₂O→MeOH) and normal-phase silica gel column chromatography [1 g, *n*-hexane-AcOEt (2:1, v/v)] to give goyagenin A (**20**, 1.5 mg, 25%).

Goyagenin A (**20**): A white powder, [α]_D²⁹ -0.4° (*c*=0.08, CHCl₃). High-resolution positive-ion FAB-MS: Calcd for C₃₀H₅₀O₅Na (M+Na)⁺: 513.3556. Found: 513.3593. IR (film): 3567, 1717 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ: 0.83, 0.90, 0.93, 1.02, 1.14, 1.44, 1.47, (3H each, all s, 30, 19, 18, 28, 29, 27, 26-H₃), 1.04 (3H, d, *J*=6.7 Hz, 21-H₃), 3.48 (1H, dd-like, 3-H), 4.74 (1H, dd-like, 22-H), 5.59 (1H, dd-like, 6-H), 5.60 (1H, d-like, 23-H). ¹³C-NMR (125 MHz, CDCl₃) δ: given in Table 1. Positive-ion FAB-MS: *m/z* 513 (M+Na)⁺.

Reduction of Goyagenin A (20) with NaBH₄ A solution of **20** (1.1 mg) in dry MeOH (0.5 ml) was treated with NaBH₄ (2 mg) and was stirred at 0 °C for 2 h. After addition of acetone to the reaction mixture, the mixture was neutralized with Dowex HCR W2 (H⁺ form) and the resin was removed by filtration. After removal of the solvent from the filtrate *in vacuo*, the residue was separated by HPLC [MeOH-H₂O (75:25, v/v)] to give 3β,22(*S*),23(*R*),24(*R*),25-pentahydroxycucurbit-5-ene (**21**, 0.5 mg, 45.5%) and its 24-diastereomer (**22**, 0.3 mg, 27.3%), and **21** was identified by comparison with reported values^{3(a)} (¹H-NMR, IR, [α]_D).

22: ¹H-NMR (270 MHz, CDCl₃) δ: 0.83, 0.89, 0.92, 1.03, 1.31, 1.33 (3H each, all s, *tert*-CH₃×7), 1.28 (3H, d-like, 21-H₃), 3.78 (1H, brs, 3-H), 3.97, 4.28, 4.44 (1H each, all m, 22, 23, 24-H), 5.61 (1H, dd-like, 6-H).

Enzymatic Hydrolysis of Momordicoside A (12) A solution of **12** (10.1 mg) in 0.1 M acetate buffer (pH 4.0, 3 ml) was treated with naringinase (Sigma Chemical Co., 30 mg) and was stirred at 40 °C for 24 h. After addition of EtOH to the reaction mixture, the solvent was removed *in vacuo*. The crude product was purified by reversed-phase (2 g, H₂O→MeOH) and normal-phase silica gel column chromatography [1 g, CHCl₃-MeOH-H₂O

(30:3:1, lower layer, v/v)] to give 3β,22(*S*),23(*R*),24(*R*),25-pentahydroxycucurbit-5-ene (**21**, 2.3 mg, 37.7%), and was identified by comparison with reported values^{3(a)} (¹H-NMR, IR, [α]_D).

Methanolysis of Goyasaponins I (9) and II (10) A solution of goyasaponins (**9**: 10.1 mg; **10**: 12.6 mg) in 9% HCl-dry MeOH (2 ml) was stirred under reflux for 30 min. After reaction, the reaction mixture was neutralized with Amberlite IRA-400 (OH⁻ form) and the resin was removed by filtration. After removal of the solvent from the filtrate *in vacuo*, the residue was separated by reversed-phase silica gel column chromatography (H₂O→MeOH) to give gypsogenin (**23**, 0.5 mg 16% from **9**; 0.7 mg, 17.9% from **10**), which was identified by comparison with reported values⁹ (¹H-NMR, IR, [α]_D).

Alkaline Hydrolysis of Goyasaponins I (9) and II (10) A solution of goyasaponins (**9**: 12.3 mg; **10**: 9.7 mg) in 5% aq. NaOH (3 ml) was stirred under reflux for 6 h. After cooling, the reaction mixture was neutralized with Dowex HCR W2 (H⁺ form) and the resin was removed by filtration. After removal of the solvent from the filtrate *in vacuo*, the residue was separated by reversed-phase (H₂O→MeOH) and normal-phase silica gel column chromatography [CHCl₃-MeOH-H₂O (65:35:10, lower layer, v/v)] to give goyaprosaponin (**24**, 4.3 mg, 59.3% from **1**; 3.2 mg, 61.5% from **2**).

Goyaprosaponin (**24**): A white powder, [α]_D²⁷ +34.8° (*c*=0.1, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₄₂H₆₄O₁₅Na (M+Na)⁺: 831.4143. Found: 831.4139. IR (KBr): 3434, 1719, 1082, 1051 cm⁻¹. ¹H-NMR (270 MHz, pyridine-*d*₅) δ: 0.79, 0.93, 0.95, 1.01, 1.27, 1.40 (3H each, all s, 25, 26, 29, 30, 27, 24-H₃), 3.26 (1H, dd-like, 18-H), 4.06 (1H, dd-like, 3-H), 4.90 (1H, d, *J*=7.3 Hz, GlcA-1-H), 5.18 (1H, d, *J*=7.6 Hz, Gal-1-H), 5.43 (1H, brs, 12-H), 9.92 (1H, s, 23-H). ¹³C-NMR (68 MHz, pyridine-*d*₅) δ: given in Table 2. Negative-ion FAB-MS: *m/z* 807 (M-H)⁻, 645 (M-C₆H₁₁O₅)⁻, 469 (M-C₁₂H₁₉O₁₁)⁻. Positive-ion FAB-MS: *m/z* 831 (M+Na)⁺.

Alkaline Hydrolysis of Goyasaponin III (11) A solution of **11** (10 mg) in 1% NaOMe-MeOH (1 ml) was stirred at room temperature (25 °C). After cooling, the reaction mixture was neutralized with Amberlite IRA-400 (OH⁻ form) and the residue was removed by filtration. After removal of the solvent from the filtrate *in vacuo*, the residue was separated by normal-phase silica gel column chromatography [1 g, CHCl₃-MeOH-H₂O (65:35:10, lower layer, v/v)] to give desacyl-goyasaponin III (**25**, 8.7 mg, 90.6%).

Desacyl-goyasaponin III (**25**): A white powder, [α]_D²⁷ -0.8° (*c*=0.2, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₄₇H₇₄O₁₈Na (M+Na)⁺: 949.4773. Found: 949.4765. IR (KBr): 3408, 1709, 1076, 1048 cm⁻¹. ¹H-NMR (500 MHz, pyridine-*d*₅) δ: 0.82, 0.96, 0.98, 1.01, 1.04, 1.25, 1.32 (3H each, all s, 25, 29, 26, 30, 24, 23, 27-H₃), 3.25 (1H, dd, *J*=4.0, 11.6 Hz, 3-H), 3.29 (1H, dd, *J*=3.7, 13.7 Hz, 18-H), 4.94 (1H, d, *J*=7.6 Hz, Xyl-1-H), 5.15 (1H, d, *J*=7.6 Hz, Glc-1-H), 5.27 (1H, d, *J*=7.3 Hz, GlcA-1-H), 5.45 (1H, brs, 12-H). ¹³C-NMR (125 MHz, pyridine-*d*₅) δ: given in Table 2. Negative-ion FAB-MS: *m/z* 925 (M-H)⁻, 793 (M-C₅H₉O₄)⁻, 763 (M-C₆H₁₁O₅)⁻, 455 (M-C₁₇H₂₇O₁₅)⁻. Positive-ion FAB-MS: *m/z* 949 (M+Na)⁺.

References and Notes

- 1) Part XX: Matsuda H., Murakami T., Nishida N., Kageura T., Yoshikawa M., *Chem. Pharm. Bull.*, **48**, 1429—1435 (2000).
- 2) Karunanayake E. H., Welihinda J., Sirimanne S. R., Sinnadarai G., *J. Ethnopharmacol.*, **11**, 223—231 (1984).
- 3) a) Okabe H., Miyahara Y., Yamauchi T., Miyahara K., Kawasaki T., *Chem. Pharm. Bull.*, **28**, 2753—2762 (1980); b) Miyahara Y., Okabe H., Yamauchi T., *ibid.*, **29**, 1561—1566 (1981); c) Okabe H., Miyahara Y., Yamauchi T., *ibid.*, **30**, 3977—3986 (1982); d) *Idem, ibid.*, **30**, 4334—4340 (1982); e) Yasuda M., Iwamoto M., Okabe H., Yamauchi T., *ibid.*, **32**, 2044—2047 (1984); f) Fatope M. O., Takeda Y., Yamashita H., Okabe H., Yamauchi T., *J. Nat. Prod.*, **53**, 1491—1497 (1990).
- 4) a) Matsuda H., Li Y., Murakami T., Yamahara J., Yoshikawa M., *Eur. J. Pharmacol.*, **368**, 237—243 (1999); b) Matsuda H., Li Y., Yoshikawa M., *Life Sci.*, **65**, PL27—32 (1999); c) Matsuda H., Li Y., Murakami T., Yamahara J., Yoshikawa M., *Bioorg. Med. Chem.*, **7**, 323—327 (1999); d) Matsuda H., Li Y., Yamahara J., Yoshikawa M., *J. Pharmacol. Exp. Ther.*, **289**, 729—734 (1999); e) Matsuda H., Li Y., Yoshikawa M., *Eur. J. Pharmacol.*, **373**, 63—70 (1999); f) Matsuda H., Shimoda H., Yoshikawa M., *Bioorg. Med. Chem.*, **7**, 1445—1450 (1999); g) Matsuda H., Li Y., Yoshikawa M., *ibid.*, **7**, 1737—1741 (1999); h) Matsuda H., Shimoda H., Yamahara J., Yoshikawa M., *Biol. Pharm. Bull.*, **22**, 870—872 (1999); i) Matsuda H., Murakami T., Yashiro K., Yamahara J., Yoshikawa M., *Chem. Pharm. Bull.*, **47**,

- 1725—1729 (1999); *j*) Matsuda H., Shimoda H., Uemura T., Yoshikawa M., *Bioorg. Med. Chem. Lett.*, **9**, 2647—2652 (1999); *k*) Murakami T., Matsuda H., Inadzuki M., Hirano K., Yoshikawa M., *Chem. Pharm. Bull.*, **47**, 1717—1724 (1999); *l*) Murakami T., Nakamura J., Matsuda H., Yoshikawa M., *ibid.*, **47**, 1759—1764 (1999); *m*) Matsuda H., Li Y., Yoshikawa M., *Life Sci.*, **66**, PL41—46 (2000); *n*) Li Y., Wen S., Yamahara J., Yoshikawa M., *Eur. J. Pharmacol.*, **387**, 339—344 (2000).
- 5) *a*) Hara S., Okabe H., Mihashi K., *Chem. Pharm. Bull.*, **34**, 1843—1845 (1986); *b*) Zhang D., Miyase T., Kuroyanagi M., Umehara K., Ueno A., *ibid.*, **43**, 966—970 (1995).
- 6) Mulholland D. A., Sewram V., Osborne R., Pegel K. H., Connolly J. D., *Phytochemistry*, **45**, 391—395 (1997).
- 7) The ^1H - and ^{13}C -NMR spectra of **1**—**11**, **20**, **24** and **25** were assigned with the aid of homo- and hetero- correlation spectroscopy (^1H — ^1H , ^1H — ^{13}C COSY), distortionless enhancement by polarization transfer (DEPT), nuclear Overhauser and exchange spectroscopy (NOESY) and heteronuclear multiple bond correlation (HMBC) experiments.
- 8) Goyaglycosides-a (**1**), -b (**2**), -c (**3**), -d (**4**), and -g (**7**) having one or two methoxyl groups in their structures were believed to be formed during the extraction or isolation procedure. The characterization of their genuine glycosides is an interesting subject for further investigation.
- 9) Matsuda H., Murakami T., Ikebata A., Yamahara J., Yoshikawa M., *Chem. Pharm. Bull.*, **47**, 1744—1748 (1999).
- 10) Frechet D., Christ B., Sorbier B. M., Fischer H., Vuihorgne M., *Phytochemistry*, **30**, 927—931 (1991).